Иммуногистохимическое исследование пролиферативных, гиперпластических и неопластических процессов в эндометрии женщин
Диссертация
Биологическое действие стероидных гормонов на эпителиальный компонент эндометрия определяется уровнем рецепторов к эстрогенам и прогестерону в клетках желез: высокая чувствительность эпителия желез к эстрогенам в течение фазы пролиферации стимулирует развитие секреторного аппарата клетки для его дальнейшей функции в фазе секреции, в свою очередь увеличение чувствительности железистого эпителия… Читать ещё >
Список литературы
- Автандилов Г. Г., Лысенко О. Н. Плоидометрия в диагностике гиперпластических процессов эндометрия // Российские медицинские вести. 2004. — Т.9, № 1. — С.22−27.
- Автандилов Г. Г. Основы количественной патологической анатомии. — М.: Медицина, 2002. -238с.
- Берпггейн Л.М. Эпидемиология, патогенез и пути профилактики рака эндометрия: стабильность или эволюция? // Практическая онкология. -2004. Т.5, № 1. — С.1−8.
- Бохман Я.В., Прянишников В. А., Чепик. О. Ф. Комплексное лечение при гиперпластических процессах и раке эндометрия. М.: Медицина, 1979. — 272с.
- Вихляева Е.М., Самедова Н. Ч. и др. Гиперпластические процессы репродуктивной системы женщин. М., 1983 — С.67−75.
- Вихляева Е.М. Руководство по эндокринной гинекологии. М.: ООО «Медицинское инфармационное агенство», 2000. — 768с.
- Давыдов С.Н. Негормональное лечение расстройств менструальной функции и климактерия. Л.: Медицина, 1974. — 174с.
- Захарцева Л.М., Воробьева Л. И., Манжура Е. П. Морфологические и иммуиогистохимические критерии прогноза при раке эндометрия. // Онкология. 2001. — Т. З, № 4. — С.252−256.
- Кондриков Н.И. Структурно-фунциональные изменения эндометрия под воздействием стероидных гормонов. // Практическая гинекология. —1999. Т.1, № 1. — С.20−25.
- Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза // Биохимия.2000. Т.65, № 1. — С.5−33.
- Костанян И.А., Астапова М. В., Старовойтова Е. В., Драницына С. М. Выделение и изучение механизма действия пептидно-белковых факторов дифференцировки, вырабатываемых активированными клетками HL-60. // Цитология. 1994. — Т. З6, № 6. — С.525.
- Кухта В.К., Морозкина Н. В., Богатырева Е. В., Сокольчик Е. Г. Молекулярные механизмы апоптоза. // Белорусский медицинский журнал. 2004. — № 1. — С.35−38.
- Лушников Е.Ф., Абросимов А. Ю. Сравнительная морфология апоптоза и некроза клеток опухолей. // Тезисы I Белорусского съезда патологоанатомов и судебных медиков. Минск. 1991. — № 2. — С. 299 300.
- Лушников Е.Ф., Абросимов А. Ю. Гибель клетки (апоптоз). М.: Медицина, 2001. — 192с.
- Лысенко О.Н., Ашхаб М. Х., Стрижова Н. В., Бабиченко И. И. Иммуиогистохимические исследования экспрессии рецепторов к стероидным гормонам при гиперпластических процессах в эндометрии // Архив патологии. 2004. — Т.66, № 2. — С.7−10.
- Манских В.Н. Морфологические методы верификации и количественной оценки апоптоза. // Бюллетень сибирской медицины. 2004. — Т.1. — С.63−70.
- Новикова B.C. Программированная клеточная гибель. / Под ред. B.C. Новикова. СПб.: Наука, 1996. 77с.
- Новожилова А.П., Плужников H.H., Новиков B.C. Программированная клеточная гибель. / Под ред. B.C. Новикова. СПб.: Наука, 1996. — С.9−29.
- Райхлин Н.Т., Райхлин А. Н. Апоптоз основные механизмы развития и роль в онкологической практике. / Под ред. C.B. Петрова, Н. Т. Райхлина. // Руководство по иммуногистохимической диагностике опухолей человека. — Казань, 2000. — С.250−265.
- Побединский Н.М., Балтуцкая О. И., Омельяненко А. И. Стероидные рецепторы нормального эндометрия. // Акушерство и гинекология. -№ 3.-2000. -С.5−8.
- Пожарисский K.M., Леенман Е. Е. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний. // Архив патологии. 2000. — № 1. — С.3−10.
- Савицкий Г. А. Локальная гиперэстрадиолемия в патогенезе гиперпластических процессов эндометрия. //Вопросы онкологии. 1991. — № 2. — С. 164−169.
- Самуилов В.Д. Биохимия программируемой клеточной смерти (апоптоза) у животных // Соровский образовательный журнал 2001. -Т.7, № 10. — С.18−25.
- Сергеев П.В., Шимановский Н. Л., Петров В. И. Рецепторы физиологически активных веществ. Волгоград: «Семь ветров», 1999. -538с.
- Серебров А.И. Рак матки. Л.: Медицина, 1968. — 326с.
- Сметник В.П., Тумилович Л. Г. Неоперативная гинекология. М.: ООО «Медицинское информационное агенство», 2001. — С.54−81.
- Сохова З.М., Артемьев В. Е., Старцева Н. М. Проблема апоптоза и процессов его регуляции в формировании акушерской патологии // Вестник РУДН. 2002. — № 1. — С.242−249.
- Топчиева О.И., Прянишников В. А., Жемкова З. П. Биопсии эндометрия. -М.: Медицина, 1978. 232с.
- Фанченко Н. Д. Адамян Л.В. и др. Гиперпластические процессы репродуктивной системы женщин. М., 1997. — № 7. — С.26−27.
- Фильченков A.A., Стойка P.C. Апоптоз и рак. Киев: Морион, 1999. -184с.
- Хмельницкий O.K. Цитологическая и гистологическая диагностика заболеваний шейки и тела матки. СПб.: СОТИС, 2000. — 336 с.
- Чепик О.Ф. Морфогенез гиперпластических процессов эндометрия. // Практическая онкология 2004. — Т.5, № 1. — С.9−15.
- Чиссов В.И., Старинский В. В. Злокачественные новообразования в России в 2000 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена, 2002. — 264 с.
- Эллиниди В.Н., Пожарисский К. М. Ядрышковые организаторы и митотический режим в гиперпластических изменениях и раке эндометрия. // Вопросы онкологии. 1999. — Т.45, № 6 — С. 636−639.
- Ярилин А.А. Апоптоз Природа феномена и его роль в целостном организме // Патол. физиол. и экспер. терапия. — 1998. — Т.2, № 1. С.38−48.
- Ambros R.A., Sheehan С.Е., Kallakury B.V., Ross J.S., Malfetano J., Paunovich E., Figge J. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma. // Mod. Pathol. 1996. — V.9. — P. l 1 651 169.
- Amezcua C.A., Zheng W., Muderspach L., Felix J.C. Down regulation of bcl-2 is a potential mark of the efficacy of progestin therapy in treatment of endometrial hyperplasia. // Gynecol. Oncol. 1999. — V.73, № 1. — P. 126−136.
- Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily // Nat. Rev. Cancer 2002. — V.2. — P.420−30.
- Athanassiadou P., Petrakakon E., Liossi A. et al. Prognostic significance of P53 bcl-2 and EGFR in carcinoma of endometrium. // Acta. Cytol. 1999. -V.43, № 6. — P.1030−1044.
- Baak J.P.A., Mutter G.L. EIN and WH094. // J. Clin. Pathol. 2005. — V.58, № 1. -P.l-6.
- Balint E.E., Vousden K.H. Activation and activities of the p53 tumour suppressor protein. //Br. J. Cancer. -2001. -V.85. -P.1813−1823.
- Basu A., Haldar S. The relationship between Bcl-2, Bax and P53: consequences for cell cycle progression and cell death. // Mol. Hum. Reprod. 1998. —V.4. — P. 1099−1109.
- Baudendistel L.J., Ruh M.F., Nadel E.M., Ruh T.S. Cytoplasmic estrogen receptor replenishment: oestrogems versus anti-oestrogens. // Acta Endocrinol. 1978. — V.89, № 3. -P.599−611.
- Bayard F., Damilano S., Robel P., Banlin E.E. Cytoplasmic and nuclear estradiol and progesterone receptors in human endometrium. // J. Clin. Endocrinol. Metab. 1978. — V.46, № 4. -P.635−648.
- Beato M. Transcriptional control by nuclear receptors. // FASEB J. 1991. — V.4, №:5. — P.2044−2051.
- Bergeron C., Ferenezy A., Toft D., Shyamala G. Immunocytochemical study of progesterone receptors in hyperplastic and neoplastic endometrial tissues. // Cancer Res. 1988. — V.48. — P.6132−6136.
- Bergqvist A., Ferno M. Oestrogen and progesterone receptors in endometriotic tissue and endometrium: comparison of different cycle phases and ages. // Human Reproduction. 1993. — V.8. — P.2211−2217.
- Bhagavan B.S., Parmley T.H., Rosenshein N.B., Jefferys J.L., Grisso J.-A., Stolley P.D. Comparison of estrogen-induced hyperplasia to endometrial carcinoma. // Obstet. Gynecol. 1984. — V.64. — P.12−15.
- Boise L.N., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G. and Tompson C.B. Bcl-x, a bcl-2 related gene that functions as dominant regulator of apoptotic cell death. // Cell 1993. — V.74. -P.597−608.
- Bokhman J.V. Two pathogenic types of endometrial carcinoma. // Gynecol. Oncol. 1983. — V. 15. — P. 10−17.
- Bouchard Ph., Marraoui J., Masai M.R. et al. Immunohistochemical localization of oestradiol and progesterone receptors in human endometrium: a tool to assess endometrial maturation. // Baillieres Clin. Obstet. Gynecol. -1991. V.5, № 1. — P. 107−115.
- Bozdogan O., Atasoy P., Erekul S., Bozdogan N., Bayram M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium. // Int. J. Gynecol. Pathol. — 2002. — V.21, № 4. — P.375−382.
- Bratton S.B., Cohen G.M. Apoptotic death sensor: an organelle’s alter ego? // Trends. Pharmacol. Sci. 2001. — V.22. — P. 306−315.
- Brustmann H., Naude S. Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues. // Pathol. Res. Pract. 1999. — V.195. — P.829−834
- Buckley C.H., Fox H. Biopsy pathology of the endometrium. // Raven Press, New York.-P. 149−165.
- Buendia B., Santa-Maria A., Courvalin J.C. Caspase-dependent proteolysis of integral and peripheral proteins of nuclear membranes and nuclear pore complex proteins during apoptosis. // J. Cell Sci 1999. — V.112 — P.1743−1753.
- Casper R.F. Regulation of estrogen/progesterone receptors in the endometrium. // Int. J. Fertil. Menopausal. Stud. 1996. — V.41, № 1. — P. 1621.
- Chan W.K., Mole M.M., Levison D.A., Ball R.Y., Lu Q.-L., Patel K., Hanby A.M. Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. // J. Pathol. 1995. — V.177. — P.241−246.
- Chittenden T., Harrington E.A., O’Connor R., Flemington C., Lutz R.J., Evan G.I. and Guild B.C. Induction of apoptosis by the Bcl-2 homologue Bak. // Nature 1995. — V.374. — P.731−733.
- Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. // Cancer. 1993. -V.71. — P. 1467−1470.
- Crescenzi E., Criniti V., Pianese M., Tecce M.F., Palumbo G. Differential expression of antiapoptotic genes in human endometrial carcinoma: bcl-XL succeeds bcl-2 function in neoplastic cells. // Gynecol. Oncol. 2000. — V.77, № 3.-P.419−428.
- Critchley H.O., Tong S., Cameron S.T., Drudy T.A., Kelly R.W. and Baird D.T. Regulation of bcl-2 gene family members in human endometrium by antiprogestin administration in vivo // J. Reprod. Fertil. 1999. — V.115. -P.389−395
- Dahmoun M, Boman K, Cajander S, Westin P, and Backstrom T. Apoptosis, proliferation and sex steroid receptors in superficial parts of human endometrium at the end of the secretory phase. // Clin. Endocrinol. Metab. — 1999. V.84. — P.1737−1743.
- Dallenbach-Hellweg G., Poulsen H. // Atlas of endometrial histopathology. -1996.
- Deligdisch L., Cohen C.J. Histologic correlation and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. // Cancer. — 1985. V.56. -P.1452−1455.
- Diebold J., Barretton G., Felchner M., Meier W., Dopfer K., Schmidt M. and Lohrs U. Bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinoma cell lines. // Am. J. Clin. Pathol. 1996. — V.105. — P.341−349.
- Dietel M. The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? // Virch. Archiv. 2001. — V.439, № 5. — P.604−608.
- Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrares, and function during apoptosis. // Annu. Rev. Biochem. 1999. — V.68. — P.383−424.
- Elhafey A.S., Papadimitriou J.C., El-hakim M.S. et al. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in begin, hyperplastic and malignant endometrium. // Arch. Pathol. Lab. Med. 2001. — V.125. — P.872−879.
- Erdem O., Erdem M., Dursun A. et al. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. // Int. J. Gynecol. Pathol. — 2003. -V.22. P.254−260.
- Feinmesser M., Halpern M., Fenig E. et al. Expression of the apoptosis-related oncogenes Bcl-2, Bax and P53 in merkel cell carcinoma: can they predict treatment response and clinical outcome? // Hum. Pathol. 1999. — V.30. — P.1367−1372.
- Ferenczy A., Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. // Am. J. Obstet. Gynecol. -1989. V.160. — P.126−131.
- Fox H. The endometrial hyperplasias. // Obstet. Gynecol. Annu. 1984. -V.13.- P. 197−209.
- Fox H., Backley C.H. The endometrial hyperplasias and their relationship to endometrial neoplasia. // Histopathology. 1982. — V.6. — P.493−510.
- Fox H., Backley C.H. Pathology for gynaecologists. 2nd edn. Edward Arnold, //London.-1991.-P.l 18−160.
- Garcia-Velasco J., Arid A. Apoptosis and the pathgenesis of endometriosis. // Semin. Reprod. Med. -2003. V.21. — P. 165−172.
- Geisler J.P., Geisler H.E., Wiemann M.C. et al. Lack of bcI-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. //Gynecol. Oncol. 1998. — V.71, № 2. -P.305−307.
- Genz T., Eiletz J., Kreuzer G. et al. Endocrine regulation of the endometrium throughout the menstrual cycle. // Geburtshilfe Frauenheikd. 1980. — V.40. -P.990−999.
- Giatromanolaki A., Sivridis E., Konkonrakis M.I., Harris A.L., Gatter K.C. Bcl-2 and p53 expression in stage I endometrial carcinoma. // Anticancer Res. 1998. -V.18. — P.3689−3693
- Glasser S.R., Aplin J.D., Guidice L.C., Tabibzadeh S. The Endomitrium. // London&New York- Taylor&Francis. 2002. — 674 p.
- Gomez-Benitez J., Diaz-Chico B.N. Time course of anterior pituitary estrogen receptor after low 17 beta-estradiol doses in ovariectomized rats. // J. Steroid Biochem. 1985. — V.23, № 1. — P.77−80.
- Gompel A., Sabourin J.C., Martin A., Yaneva H., Audouin J., Decroix Y. and Poitout P. Bcl-2 expression in normal endometrium during the menstrual cycle. // Am. J. Pathol. 1994. — V.144. — P. 1195−1202.
- Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in sith terminal deoxynuclejtidyl transferase and nick traslation assys. // Cancer Res. 1993. — V.53. — P. 1945−1951.
- Gottlieb R.A. Mitochondria: execution central // FEBS Letters. 2000. -V.482 — P.6−12.
- Grio R., Curti A., Gobbi F., Piacentino R. Estrogen and progestin treatment in postmenopause. Effects on the endometrium. // Minerva Ginecol. 1998. -V.50., № 12. — P.553−556.
- Hadcock J.R., Malbon C.C. Regulation of receptor expression by agonists: transcriptional and post-transcriptional control. // Trends Neurosci. — 1991. — V.14. -P.242−247.
- Harada T., Kaponis A., Iwabe T., Taniguchi F., Makrydimas G., Sofikitis N., Paschopoulos M., Paraskevaidis E. and Terakawa N. Apoptosis in human endometrium and endometriosis // Human Reproduction Update 2004. — V.10, № 1 — P.29−38.
- Haunstetter A., Izumo S. Apoptosis: Basic Mechanisms and Implications for Cardiovascular Disease. // Circ. Res. 1998. — V.82. — P. l 111−1129.
- Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. // Carcinogenesis. -2000. V.21. -P.427−433.
- Hendrickson M.R., Ross J.C., Kempson R.L. Toward the development of morphologic criteria for well-differentiated adenocarcinoma of the endometrium. // Am. J. Surg. Pathol. 1983. — V.7. -P.819−838.
- Henzl M.R., Segre E.H. Physiology of human menstrual cycle and early pregnancy. A review of recent investigations. // Contraception. 1970. — V.l. -P.315−338.
- Hernandez E. Pathological findings and prognosis from uterine malignancies. // Curr. Opin. Obstet. Gynecol. 1993. — V.5. — P.480−485.
- Ho S.P., Tan K.T., Pang M.W., Ho T.H. Endometrial hyperplasia and the risk of endometrial carcinoma. // Singapore Med. 1997. — V.38. — P. l 1−15.
- Hopwood D., Levison D.A. Atrophy and apoptosis in the cyclical human endometrium. // J. Pathol. 1976. — V. l 19, № 3. — P.159−166.
- Horn L.C., Bilek K., Schnurrbusch U. Endometrial hyperplasias: histology, classification, prognostic significance and therapy. // Zentralbl. Gynecol. -1997. V.119. — P.251−259.
- Hudock J.A., Hanau C.A., Christen R., Bibbo M. Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives. // Diagn. Cytopathol. 1996. — V. l5, № 1. — P.78−83.
- Hunter J.E., Tritz D.E., Howell M.G., DePriest P.D., Gallion H.H., Andrews S J. et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. // Gynecol. Oncol. 1994. — V.55. -P.64.71.
- Hussain S.P., Hollstein M.N., Harris C.C. The p53 tumor supressor gene: at the crossroads of molecular carcinogenesis, molecular epidemioogy and cancer risk assessment. // Ann. N.Y. Acad. Sci. 2000. — V.919. — P.79−85.
- Inoue M., Okayama A., Fujita M., Enomoto T., Sakata M., Tanizawa O., Neshima H. Clinicopathological characteristics of P53 overexpression in endometrial cancers. // Int. J. Cancer 1994. — V.58. — P. 14−19.
- Isola J J. Immunohistochemical demonstration of adrogen receptor in breast cancer an its relationship to other prognostic factors // J. of Pathology. 1993.- V.170, № 1. -P.31−35.
- Jackel M.C., Dorudian M.A., Marx I., Brinck U., Schauer A., Steiner W. Spontaneous apoptosis in laryngeal squmous cell carcinoma is independent of Bcl-2 and Baxprotein expression. // Cancer. 1999. — V.85. — P.591−599.
- Jacques S.M., Qureshi F., Munkarah A., Lawrence W.D. Interinstitutional surgical pathology review in gynecologic oncology: endometrial cancer in hysterectomy specimens. // Int. J. Gynecol. Pathol. 1998. — V.17. — P.42−45.
- Janicek M.F., Rosenshein N.B. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. // Gynecol. Oncol. — 1994. V.52. — P.373−378.
- Janne O., Isomaa V., Isotalo H., Kokko E., Vierikko P. Uterine estrogen and progestin receptors and their regulation. // Ups. J. Med. Sci. Suppl. -1978. -V.22 P.62−70
- Jensen E.V. Steroid hormones, receptors, and antagonists. // Ann. N. Y. Acad. Sci. 1996.-V.784.-P.1−17.
- Jensen E.V., Jacobson H.I. Basic guides to the mechanism of estrogen action. // Recent. Prog. Horm. Res. 1962. — V.18. — P.387.
- Jones R.K., Searle R.F., Stewart J.A., Turner S., Bulmer J.N. Apoptosis, bcl-2 expression, and proliferative activity in human endometrial stroma and endometrial granulated lymphocytes. // Biol. Reprod. 1998. — V.58. — P.995−1002.
- Kaku N., Kamura T., Hirakawa T., Sakai K., Amada S., Kobayashi H., Nakano H. Endometrial carcinoma associated with hyperplasia — immunohistochemical study of angiogenesis and p53 expression. // Gynecol. Oncol. 1999. — V.72. — P.51−55.
- Kassis J.A., Gorski J. On the mechanism of estrogen receptor replenishment: recycling, resynthesis and/or processing. // Mol. Cell. Biochem. 1983. -V.52, № 1. — P.27−36.
- Kerr J.F.R., Wyllie F.N., Currie A.R. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. // Brit. J. Cancer. 1972. — V.26, № 2. — P.239−257.
- Khong T., Abdul Rahman H. Bcl-2 expression delays postpartum involution of pregnancy-induced vascular changes in the human placental bed. // int. J. Gynecol. Pathol. 1997. -V. 16, № 2. — P. 138−142.
- Kiechle M., Hinrichs M., Jacobsen A., Luttges J., Pfisterer J., Kommoss F., Arnold N. Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization. // Am. J. Pathology 2000. — V.156. -P.1827−1833.
- King W.J., Desombre E.R., Jensen E.V., Green G.L. Comparison of immunocytochemical and steroid binding assaya for estrogen receptor in human tumors. // Cancer. 1985. — V.45. — P.293.
- King S.A., Adas A. A., LiVolsi V.A. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. // Cancer. 1995. -V.75. -P.2700−2705.
- Kinzler K.W., Vogelstein B. Live (and death) in malignant tumor. // Nature. -1996. V.379. -P.19−20.
- Kistner R. Estrogens and endometrial carcinoma // Obstet. Gynecol. — 1976. — V.48. -P.479−482.
- Koh E.A., Illingworth P.J., Duncan W.C., Critchley H.O. Immunolocalisation of bcl-2 protein in human endometrium in the menstrual cycle and simulated early pregnancy. // Hum. Reproduction 1995. — V. 10, № 6 — P. 1557−1562.
- Kokawa K., Shikone T., Nakano R. Apoptosis in human uterine endometrium during the menstrual cycle. // Journal of Clin. Endocrinol, and Metab. 1996.- V.81, № 11. P.4144−4147.
- Kokawa K., Shikone T., Otani T., Nishiyama R., Ishii Y., Yagi S. and Yamoto M. Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. // Hum. Reproduction 2001a. -V.16, № 10. -P.2211−2218.
- Konno R., Yamakawa H., Utsunomiya H., Ito K., Sato S. and Yajima A. Expression of survivin and Bcl-2 in the normal human endometrium. // Mol. Hum. Reprod. 2000. — V.6. — P.529−534.
- Kontula K. Progesterone-binding proteins from endometrium and miometrium of sheep uterus: a comparative study. // Acta Endocrinol (Copenh). 1975. — V.78. -P.596−603.
- Korsmeyer S.J. Bcl-2 gene family and the regulation of programmed cell death. // Cancer Res. 1999. -V.59 — P. 1693−1700.
- Koshiyama M., Konishi I., Wang D. et al. Immunohistochemical analysis of P53 protein overexpression in endometrial carcinomas: inverse correlation with sex steroid receptor status. // Virchows Arch. 1993. — V.423, № 2. -P.265−271.
- Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H. and Jones M. W Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of literature. // Mod. Pathol. 2000. — V.13. — P.379−388.
- Kovalev S., Marchenko N., Chalas E. et al. Loss of the p53 function in uterine papillary serous carcinoma. // Human Pathol. 1998. — V.29. — P.613−618.
- Krajewski S., Krajewska M., Shabaik A. et al. Immunohistochemical determination of in vivo distribution of Bax. A dominant inhibitor of bcl-2. // Am. J. Pathol. 1994. — V.145. -P.1323−1326.
- Kreitmann B., Bayard F. Oestrogen and progesterone receptor concentrations in human endometrium during gestation. // Acta Endocrinol. (Copenh). -1979. V.92, № 3. — P.547−552.
- Kroemer G., Dallaporta B., Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. // Annu. Rev. Physiol. 1998. -V.60.-P.619−642.
- Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B., Wild-type p53 ia a cell cycle checkpoint determinant folowing irradiation. // Proc. Natl. Acad. Sci. USA. 1992. — V.89. — P.7491−7495.
- Kumar S., Zhu L.-J., Polihronis M. et al. Progesterone induces calcitonin gene expression in human endometrium within the putative window of implantation. // J. Clin. Endocrinol. Metab. 1998. — V.83. — P.4443−4450.
- Kurman R.J., Kaminski P., Norris H. The behavior of endometrial hyperplasia: A long term study of «untreated» hyperplasia in 170 patients. // Cancer. 1985.-V.56.-P.403.
- Kurman R.J., Norris H.J. Evalution of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. // Cancer. — 1982. V.49. — P.2547−2559.
- Lawen A. Apoptosis an introduction // BioEssays. — 2003. — V.25. — P. 888 896.
- Lax S.F., Pizer E.S., Ronnett B.M., Kurman R.J. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone preceptor expression. // Hum. Pathol. 1998. — V.29. -P.551−558.
- Lenton E.A., Cripps K., Sulaiman R., Sobowale O., Ryle M., Cooke I.D. Plasma prolactin concentrations during conception and first ten weeks of human pregnancy. // Acta Endocr. 1982. — V.65. — P.295−300.
- Levine A.J., Momand J., Finlay C.A. The p53 tumor supressor gene. // Nature. 1991. — V.351.-P.453−456.
- Li S.F., Shiozama T., Nakayama K., Nikaido T., Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (P53 and Rb), and cyclin E in uterine endometrioid carcinoma. // Cancer. 1996. — V.77. — P.321−329.
- Longacre T.A., Kempson R.L., Hendrickson M.R. Endometrial hyperplasia, metaplasia and carcinoma. / In: Fox H., Wells M. (eds.) Obstetrical and Gynaecological Pathology, 4lh edn. Churchill Livingstone, Edinburgh, 1995. — P.421−510.
- Lu Q., Abel P., Foster C., Lalani E.N. Bcl-2: role in epithelial differentiation and oncogenesis. // Hum. Pathol. 1996. — V.27. — P. 102−110.
- Marone M., Fernandina G., Macchia G. et al. Bcl-2, Bax, Bcl-xl and Bcl-xs expression in neoplastic and normal endometrium. // Oncology. 2000. -V.58, № 1. — P.161−168.
- Marsden D.E., Hacker N.F. Optimal management of endometrial hyperplasia. // Best Practice & Research Clin. Obst. & Gyn. 2001. — V.15, № 3. — P.393−405.
- Mayo J.L. Healthy menstrual cycle. // Clinical Nutrition Insights. 1997. -V5.-P.l-8.
- McClelland R.A., Wilson D., Leake R., Finlay P., Nicholson R.I. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. British Quality Control Group. // Eur. J. Cancer. 1991. -V.27, № 6. -P.711−715.
- Metzger D.A. Cyclic changes in endometriosis implants. / In: The current status of endometriosis research and management. Ed. I. Brosens, J. Donnez. — Carndorth. Pathenon Publishing Group Ltd, 1993. — P.89−108.
- Milgrom E., Baulieu E.E. Progesterone in uterus and plasma. IV. Progesterone receptor (s) in guinea pig uterus cytosol. // Steroids. 1970. -V.16. -P.741−754.
- Miyashita Т., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. // Cell. 1995. — V.80. — P.293−299.
- Moulton B.C., Motz j., Serdonillo C., Akcali K.C., Khan S.A. Progesterone withdrawal and ru-486 treatment stimulate apoptosis in specific uterine decidual cells. // Cell Death Dsiff. 1997. — V.4. — P.76−81.
- Mozetti S., Ferrandina G., Marone M. et al. Expression of bcl-2, bax, bcl-xL and bcl-xs in endometrial and cervical tissues. // Can. Detect. Prevent. — 2000. V.24. -P.536−541.
- Murakami T. Endometrial steroid receptor during normal menstrual cycle and physiopathology of nidaton. // Acta. Obstet. Gynecol. Jap. 1984. — V.36, № 1. — P.85−93.
- Mutter G.L., Wada H., Faquin W.C., Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. // Mol. Pathol. 1999. — V.52. — P.257−262.
- Naismith J.H., Sprang S.R. Modularity in the TNF-receptor family. // Trends. Biochem. Sci. 1998. — V.23. -P.74−79.
- Nakamura T., Nomura S., Sakai T., Niriya S. Expression of Bcl-2 oncoprotein in gastrointestinal and uterine carcinomas and their premalignant lesions. // Hum. Pathol. 1997. — V.28. — P.309−315.
- Niikura H., Sasano H., Kaga K., Sato S., Yajima A. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. // Hum. Pathol. 1996. — V.27. — P.282−289.
- Norris H.J., Becjer R.L., Mikel U. A comparative morphometric and cytophotometric study of endometrial hyperplasia, atypical hyperplasia and carcinoma. // Human. Path. 1989. — V.20. — P.219−223.
- Noyes R.W., Haman J.O. Accuracy of endometrial dating. Correlation of endometrial dating with basal body temperature and menses. // Fertil. Steril. -1953. V.4. — P.504−517.
- Nurse P. Checkpoints pathways come of age. // Cell. 1997. — V.91. — P.865−867.
- Oehler M.K., Rees M.C., Bicknell R. Steroids and the endometrium. // Curr. Med. Chem. 2000. — V.7, № 5. — P.543−560.
- Oltvai Z.N., Milliman C.L. and Korsmeyer S.J. Bcl-2 heterodimerizes in vitro with a conserved homolog, Bax, the accerelated programmed cell death. // Cell. 1993. — V.74. — P.609−619.
- Otsuki Y., Misaki D., Sugimoto O, Ito Y., Tskjimoto Y., Akao Y. Cycle bcl-2 gene expression in human uterine endometrium during menstrual cycle. // Lancet. 1994. — V.344, № 8914. -P.28−29.
- Otsuki Y. Apoptosis in human endometrium: apoptotic detection methods and signaling. // Med. Electron. Microsc. 2001. — V.34. — P. 166−173.
- Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. // Mol. Cell. Biol. 1995. -V.15. -P.3032−3040.
- Palazzo J.P., Mercer W.E., Kovatich A.J., McHugh M. Immunohistochemical localization of p21 in normal, hyperplastic and neoplastic uterine tissue. // Hum. Pathol. 1997. — V.27. — P.60−66.
- Pecci A., Scholz A., Pelster D., Beato M. Progestins prevent apoptosis in a rat endometrial cell line and increase the ratio of bcl-XL to bcl-XS. // J. Biol. Chem. 1997. — V.272. — P. 11 791−11 798.
- Pierro E., Minici F., Alesiani O. et al. Stromal-epithelial interactions modulate estrogen responsiveness in normal human endometrium. // Biol. Reprod. — 2001. -V.64. -P.831−838.
- Piquette G.N., Tilly J.L., Prichard L.E., Simon C., Polan M.L. Detection of apoptosis in human and rat ovarian follicles // J. Soc. Gynecol. Invest. 1994. — V.l. -P.297.
- Pisani A.L., Barbuto D.A., Chen D., Ramos L., Lagasse L.D., Karlan B.Y. HER-2/neu, P53 and DNA analyses as prognosticators for survival in endometrial carcinoma. // Obstet. Gynecol. 1995. — V.85. — P.729−734.
- Pluquet O., Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. //Cacer. Lett. 2001. — V.174. -P.l-15.
- Pollard J.W., Pacey J., Cheng S.V., et al. Estrogens and cell death in murine uterine luminal epithelium. // Cell Tissue Res. 1987. — V.249, № 3. — P.533−540.
- Ponder B. Gene losses in human tumors. // Nature. 1988. — V.335. — P.400−402.
- Press M.F., Nousek-Goebl n., King W.J. et al. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. // Lab. Invest. 1984. — V.51. — P.495.
- Quirk S.M., Currie W.B. Uterine steroid receptor changes associated with progesterone withdrawal during pregnancy and pseudopregnancy in rabbits. // Endocrinology. 1984. — V. l 14. — P. 182−191.
- Raff M., Bares B.A., Burne J.F. et al. Programmed cell death and the control of cell survival: lessons from the nervous system. // Science. — 1993. V.262. -P.695−697.
- Rao L., Perez D., White E. Lamin proteolysis facilitates nuclear events during apoptosis. //J. Cell. Biol. 1996. -V.135. — P. 1441−1455.
- Reed J.C. Bcl-2 and the regulation of programmed cell death. // Cell. Biol. -1994.-V.124.-P.1−6.
- Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. // Curr. Opin. Oncol. — 1995. V.7, № 6. — P.541−546.
- Reed J.C. Double identity for proteins of the Bcl-2 family. // Nature. 1997. — V.387. — P.773−776.
- Robbins S.L., Cotran R.S., Kumar V., Collins T. Robbins' Pathologic Basis of Disease. 6th ed. Philadelphia, 1999. -P.132.
- Robles A. I, Harris C.C. p53-mediated apoptosis and genomic instability diseases. // Acta. Oncol. 2001. — V.40 — P.696−701.
- Rotello R., Lieberman R.C., Lepoff R.B. and Gerschenson L.E. Characterization of uterine epithelium apoptotic cell death kinetics and regulation by progesterone and RU 486. // Am. J. Pathol. 1992. — V.140. -P.449−456.
- Runowicz C.D., Nuchtern L.M., Braunstein J.P., Jones J.G. Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. // Gynecol. Oncol. 1990. — V.38, № 3. -P.437−441.
- Saegusa M., Kamata Y., Isano M., Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immonoreactivity in endometrial endometrial carcinoma. // J. Pathol. 1996. — V. 180. — P.275−282.
- Saegusa M., Okayasau I. Down-regulation of Bcl-2 expression is closely related to squamous differentiation and progesterone therapy in endometrial carcinoma. // J. Pathol. 1997b. — V.182. -P.429−436.
- Saegusa M., Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. // Cancer. — 1998. — V.83. -P.111−121.
- Sakuragi N., Ohkouchi T., Hareyama H., Ikega K., Watari H., Fujimoto T., Kuwabara M., Yamamoto R., Sagawa T., Fujino T., Fujimoto S. Bcl-2 expression adn prognosis of patiens with endometrial carcinoma. // Int. J. Cancer. 1998.- V.79.-P.153−158.
- Sakuragi N., Salah-eldin A.E., Watari H., Itoh T., Inoue S., Moriuchi T., Fujimoto S. Bax, Bcl-2 and p53 expression in endometrial cancer. // Gynecol. Oncol. 2002. — V.86. — P.288−296.
- Sale R., Sylander K., Hall P.A. Why is P53 protein stabilized in neoplasia? Some answers but many more questions. // J. Pathol. 1998. — V.184. -P.348−350.
- Savill J. Phagocytic docking without shoking. // Nature. 1998. — V.392. -P.442−443.
- Skov B.G., Broholm H., Engel U., Franzmann M.B., Nielsen A.L., Lauritzen A.F., Skov T. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. // Int. J. Gynecol. Pathol. -1997. V.16, № 1. — P.33−37.
- Scully R.E., Bonfiglio T.A., Kurman R.J., Silverberg S.G., Wilkinson E.J. Uterine corpus in Histologic typing of tumors of the female genital tract (WHO-Fascicle). //Heidelberg, Springer-Verlag, 1994. -P.26−28.
- Sherman A.I., Brown S. The precursors of endometrial carcinoma. // Am. J. Obstet. Gynecol.- 1979.-V.135.-P.947−956.
- Shikone T., Kokawa K., Yamoto M., Nakano R. Apoptosis of the human ovary and uterine endometrium during the menstrual cycle. // Hormone Res. -1997. V.48, № 1. -P.27−34.
- Shroyer K.R., Stephensen J.K., Silverberg S.G., Marcham N., Shroyer A.L., Wilson M.L. Telomerase expression in normal endometrium, endometrial hyperplasia and endometrial adenocarcinomas. // Int. J. Gynecol. Pathol. -1999. V.16. -P.219−224/
- Silverberg S.G., Mutter G.L., Kubik-Huch P.A., Tavassoli F.A. Endometrial Tumours and related Lesions // WHO Classifications of Tumours, Pathology and Genetics / Tumours of the Breast and Female Genital Organs. IARC Press, 1994. -P.221−232.
- Silverberg S.G. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. // Mod. Pathol. 2000. — V.13. — P.309−327.
- Silverberg S.G., deGiorgi L.S. Histopathologic analysis of preoperative radiation therapy in endometrial carcinoma. // Am. J. Obstet. Gynecol. -1974. V. 119. — P.698−704.
- Silverberg S.G., Kurman R.J. Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of Tumor Pathology, AFIP Fascicle. 3rd series. -Springer Verlag, 1992. V.3. — P.47−89.
- Sivridis E., Fox H., Buckley C.H. Endometrial carcinoma: two or three entities? // Int. J. Gynecol. Cancer. V.8. — P. 183−188.
- Sivridis E., Giatromanolaki A., Konkonrakis M., Anastasiadis P. Endometrial Carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. // Virchows Arch. 2001. — V.438, № 4. -P.470−477.
- Sivridis E., Giatromanolaki A., Koukourakis M., Agnatis N. Lectin-binding patter in normal, hyperplastic and neoplastic endometrium: the prognostic value of concanavalin. // Virch. Arch. 2000. — V.436. — P.52−58.
- Sivridis E. Histological evaluation of the endometrium: from hyperplasia to cancer. // Eur. J. Gynaecol. Oncol. 1996. — V.5." - P.440−442.
- Sommers S.C. The significance of endometrial hyperplasias / In: New concepts in gynecological oncology. Philadelfia, 1966. -P.356−365.
- Sung C.J., Zneng Y., Quddus M.R., Kang X., Zhang Z.-F., Lauchlan S.C. and Zheng W. p53 as a significant prognostic marker in endometrial carcinoma. // Int. Gynecol. Cancer 2000. — V.10. — P. 119−127.
- Tabibzadeh S. Signals and molecular pathways involved in apoptosis with special emphasis on human endometrium. // Hum. Reprod. 1995. — V.l. — P.303−323.
- Takai N., Miyazaki T., Nishida M., Nasu K., Miyakawsa I. Survivin expression correlates with clinical stage, histological grade, innvasive behavior and survival rate in endometrial carcinoma. // Cancer Lett. 2002. -V.l84, № 1. — P. 105−116.
- Tamaya T., Murakami T., Okada H. Concentrations of steroid receptors in normal human endometrium in relation to the day of the menstrual cycle. // Acta. Obstet. Gynecol. Scand. 1986. — V.65. — P. 195−198.
- Taskin M., Lallas T.A., Barber H.R., Sherchuk M.M. bcl-2 and p53 in endometrial adenocarcinoma. // Mod. Pathol. 1997. — V.10, № 7. — P.728−734.
- Tavassoli F., Kraus F.T. Endometrial lesions in uteri resected for atypical endometrial hyperplasia. // Am. J. Clin. Pathol. 1978. — V.70. — P.770−779.
- Taymor M.L. The use of luteinizing-releasing hormone in genecology. // Fertil. Steril. 1974.- V.25.-P.992−1005.
- Teleman S., Mihailovici M.S., Hilgarth M., Freudenberg N., Bettendorf H. p53 and steroid receptors support double endometrial cancinogenesis. // Rev. Med. Chir. Soc. Med. Nat. Iasi. 1999. — V.103. -P.131−135.
- Teleman S., Mihailovici M.S. Value of steroid receptors assessment in atypical endometrial hyperplasia // Rev. Med. Chir. Soc. Med. Nat. Iasi. — 2003. V.107, № 4. -P.813−816.
- Terakawa N., Kigawa J., Taketani Y., Yoshikawa H., Yajima A., Noda K., Okada H., Kato J. et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. // J. Obstet. Gynaecol. 1997. — V.23. -P.223−230.
- Trogovac T.C., McGauphy V.R., Neemann T.H. Bcl-2 expression in endometrial hyperplasia and carcinoma. // Am. J. Clin. Pathol. — 1995. — V.104. -P.342.
- Trope C.G., Marth C., Scheistroen M., Abeler V.M. Review Endometrial hyperplasia diagnosis and treatment. // Tidsskr Nor Laegeforen. — 1999. -V.l 19. -P.2030−2034.
- Utaaker E., Iversen O., Skaarland E. The distribution and prognostic implications of steroid receptors in endometrial carcinomas. // Gynecol. Oncol. 1987. — V.28. — P.89−100.
- Vaskivuo T.E., Stenback F., Karhumaa P., Risteli J., Dunkel L. and Tapanainen J.S. Apoptosis and apoptosis-related proteins in human endometrium. // Mol. Cell. Endocrinol. 2000. — V. l65. — P.75−83.
- Vaskivuo T.E., Stenback F. and Tapanainen J. Apoptosis and apoptosis related factors Bcl-2, Bax, TNF-alpha and NF-kB in human endometrial hyperplasia and carcinoma. // Cancer. 2002. — V.95, № 7. — P.1463−1471.
- Vecek N., Nola M., Marusic M. et al. Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. // Acta. Obstet. Gynecol. Scand. 1994. — V.73. — P.730−733.
- Vedeckis W.V. Nuclear receptors, transcriptional regulation, and oncogenesis. //Proc. Soc. Experim. Biol. Med. 1992. — V.199. — P. l-12.
- Vignon F., Rochefort H. Regulation of estrogen receptors in ovarian-dependent rat mammary tumors. I. Effects of castration and prolactin. // Endocrinology. 1976. — V.98. -P.722−730.
- Vogelstein B., Kinzler K.W. p53 function and dysfunction. // Cell. 1992. -V.70. — P.523−526.
- Wahl G. M, Carr A.M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. // Nat. Cell. Biol. 2001. — V.3. -P.277−286.
- Walker P.R., Leblanc J., Smith B., Pandey S., Sikorska M. Detection of DNA fragmentation and endonucleases in apoptosis // Methods. 1999. — V.17. -P.329−338.
- Warnke R., Levy R. Detection of T and B cell antigens with hybridoma monoclonal andibodies. A biotin-avidin-horseradish peroxidase method. // J. Histochem. Cytochem. 1980. — V.28. -P.771.
- Wehling M. Looking beyond the dogma of genomic steroid action: insights and facts of the 1990s. // Mol. Med. 1995. — V.73. — P.439- 447.
- Wentz W.B. Progestin therapy in endometrial hyperplasia. // Gynecol. Oncol. 1974. — V.2. — P.362−367.
- Winkler B., Alvarez S., Richart R.M., Crum C.P. Pitfulls in the diagnosis of endometrial hyperplasia. // Obstet. Gynecol. 1984. — V.64. — P. 185−193.
- Автор диссертации приносит слова искренней благодарности за помощь в осуществлении настоящей работы:
- Научному руководителю заведующему кафедрой патологической анатомии медицинского факультета Российского университета дружбы народов профессору, доктору медицинских наук И. И. Бабиченко.
- Доцентам кафедры патологической анатомии медицинского факультета Российского университета дружбы народов кандидату медицинских наук А. Л. Владимирцевой и кандидату медицинских наук Н. М. Харченко.
- Врачам патологоанатомического отделения Госпиталя для ветеранов войн № 2: В. Н. Кукушкину и заведующей отделением доктору медицинских наук Л. В. Гундоровой.
- Заведующему патологоанатомическим отделением Городской клинической больницы № 4 г. Москвы профессору, доктору медицинских наук К. А. Рогову.
- Кафедре патологической физиологии медицинского факультета РУДН.